Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

In this study, researchers found that applying mometasone furoate 0.1% cream combined with adapalene 0.1% gel resulted in significantly greater hair regrowth over 12 weeks compared to mometasone furoate cream alone in patients with alopecia areata.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

In this extended follow-up of the PALOMA-2 trial, no significant differences in overall quality of life were observed between first-line treatments for metastatic breast cancer, but palbociclib plus letrozole showed some benefits regarding side-effects and hair loss.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This document provides a legal disclaimer and offers no research findings.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

This review discusses common skin eruptions caused by biologics in treating inflammatory bowel disease and proposes tailored therapeutic approaches for managing these adverse reactions.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This study found that dimethyl fumarate improved delayed wound healing in Il36rn-/- mice by reducing neutrophil extracellular trap formation and oxidative stress.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

This study found that prototype right heart circulatory assist devices significantly improved hemodynamics and reduced pulmonary vascular resistances in piglet models of acute hemodynamic shock.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

Adequate steroid treatment needed to limit bone loss in PMR patients.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.